Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02002312
Other study ID # CMO2009/322
Secondary ID
Status Completed
Phase Phase 2
First received November 29, 2013
Last updated August 12, 2015
Start date August 2011
Est. completion date June 2015

Study information

Verified date August 2015
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

To determine the efficacy of multiple doses Lutetium-177-DOTA-girentuximab in patients with advanced clear cell renal cell carcinoma using RECIST criteria.


Description:

This is a Phase II study using Lu-177-DOTA-girentuximab for treatment of patients with advanced clear cell renal cell carcinoma. The trial requires 14 patients. CT scans will be carried out at baseline and after 12 weeks, for response assessment using RECIST criteria.

Patients will initially receive 5 mCi/10 mg Indium-111-DOTA-girentuximab antibody (an imaging dose preceeding Lu-177-girentuximab treatment). Whole body and blood measurements of radioactivity will be obtained on at least three occasions for one week to determine targeting and dosimetry. Only if at least one known and evaluable metastatic lesion is visualized with In-111-DOTA-girentuximab, therapeutic Lu-177-DOTA- girentuximab will be administered the following week. In the absence of disease progression and after recovery from toxicity, patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments. Only patients who have normal pharmacokinetics on the preceding diagnostic In-111-girentuximab study (indicative of human antichimeric antibodies (HACA) negativity) are eligible for retreatment.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date June 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria:

- Patients with proven advanced and progressive RCC of the clear cell type

- Presence of RECIST v.1.1 evaluable lesions, all < 5 cm

- Performance status: Karnofsky > 70 %

- Laboratory values: • White blood cells (WBC) > 3.5 x 109/l • Platelet count > 150 x 109/l • Hemoglobin > 6 mmol/l • Total bilirubin < 2 x upper limit of normal (ULN) • ASAT, ALAT < 3 x ULN (< 5 x ULN if liver metastases present) • MDRD = 40 ml/min

- Negative pregnancy test for women of childbearing potential (urine or serum)

- Age over 18 years

- Written informed consent

Exclusion criteria:

- Known or suspected CNS metastases including leptomeningeal metastases. History or clinical evidence of (CNS) metastases (unless they are previously-treated CNS metastases and patients meet all 3 of the following criteria: are asymptomatic, have had no evidence of active CNS metastases for =3 months prior to enrollment, and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days)

- Untreated hypercalcemia

- Chemotherapy, external beam radiation, immunotherapy or angiogenesis inhibitors or mTOR inhibitors within 4 weeks prior to study. Limited field external beam radiotherapy to prevent pathological fractures is allowed , when unirradiated, evaluable lesions elsewhere are present.

- Cardiac disease with New York Heart Association classification of III or IV

- Patients who are pregnant, nursing or of reproductive potential and are not practicing an effective method of contraception

- Any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory abnormalities, which in the judgment of the investigator will significantly affect patients' clinical status

- Life expectancy shorter than 4 months.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Lu-177-DOTA-girentuximab
Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111. Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments.

Locations

Country Name City State
Netherlands Radboud University Medical Center Nijmegen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor response Evaluation according to RECIST criteria 12 weeks No
Secondary Progression free survival Progression free survival is defined as the time measured from the day of first administration of Lu-177-girentuximab to first progression or death, whichever comes first. 3 years No
Secondary Toxicity Toxicity defined by NCI Common Terminology Criteria for Adverse Events (CTCAE v3.0) up to 14 weeks after last therapeutic infusion Yes
See also
  Status Clinical Trial Phase
Completed NCT01510119 - Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT01896271 - High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Phase 2
Recruiting NCT06059014 - Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer Phase 1/Phase 2
Active, not recruiting NCT05122546 - CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Phase 1
Active, not recruiting NCT04904302 - Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer Phase 2
Recruiting NCT04510597 - Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial Phase 3
Terminated NCT02781506 - Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma Phase 2
Recruiting NCT06399419 - CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Phase 1
Not yet recruiting NCT06361810 - PSMA Therapy and Immunotherapy in Kidney Cancer Phase 1/Phase 2
Recruiting NCT06428708 - [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma Early Phase 1
Recruiting NCT04370509 - Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery Phase 2
Recruiting NCT05012371 - Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer Phase 2
Terminated NCT03334409 - Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery Phase 2
Completed NCT02848768 - Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma N/A
Recruiting NCT05361720 - Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Phase 2
Terminated NCT03260504 - Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Phase 1
Terminated NCT01391130 - A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT04388852 - DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Phase 1
Recruiting NCT05879471 - 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma Phase 2
Recruiting NCT06349642 - Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform